This is part two of a two-part series examining the venture capital landscape in the life science research tools and molecular diagnostics markets. To read part one, click here.

NEW YORK (GenomeWeb News) – Despite the recently soured economy, venture capitalists have remained relatively optimistic about investment opportunities in the life science research tools and molecular diagnostics sectors, according to industry insiders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.